68064-69-7

Basic information

• Product Name: Z-2-(2,3-Dichlorophenyl)methylene-3-oxobutanoic acid methyleater
• Synonyms: Z-2-(2,3-Dichlorophenyl)methylene-3-oxobutanoic acid methyleater;2,3-DICHLOROBENZILIDENE METHYL ACETOACETATE(FELODIPINE INTERMEDIATES );QQXPSPWWWCQBFM-TWGQIWQCSA-N
• CAS NO: 68064-69-7
• Molecular Formula: C₁₂H₁₀Cl₂O₃
• Molecular Weight: 273.112
• Mol File: 68064-69-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 383.597°C at 760 mmHg
• Flash Point: 157.16°C
• Appearance: /
• Density: 1.337g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.575
• CAS DataBase Reference: Z-2-(2,3-Dichlorophenyl)methylene-3-oxobutanoic acid methyleater(CAS DataBase Reference)
• NIST Chemistry Reference: Z-2-(2,3-Dichlorophenyl)methylene-3-oxobutanoic acid methyleater(68064-69-7)
• EPA Substance Registry System: Z-2-(2,3-Dichlorophenyl)methylene-3-oxobutanoic acid methyleater(68064-69-7)

Safety Data

• Hazardous Substances Data: 68064-69-7(Hazardous Substances Data)

Usage

General Description

Z-2-(2,3-Dichlorophenyl)methylene-3-oxobutanoic acid methyleater is a chemical compound with the molecular formula C11H9Cl2O3. It is a methyl ester derivative of Z-2-(2,3-Dichlorophenyl)methylene-3-oxobutanoic acid, which is a known herbicide. The chemical is used as an agricultural herbicide to control weeds and unwanted plants in various crop fields. It works by inhibiting the growth of certain plant species, ultimately leading to their death. However, it is important to handle and use this chemical with caution, as it can be harmful if ingested, inhaled, or comes into contact with the skin.

InChI:InChI=1/C12H10Cl2O3/c1-7(15)9(12(16)17-2)6-8-4-3-5-10(13)11(8)14/h3-6H,1-2H3/b9-6-

Upstream product

• 105-45-3 acetoacetic acid methyl ester 
• 6334-18-5 2,3-dichlorobenzylaldehyde 
• 110-89-4 piperidine 

Downstream Products

• 88150-49-6 2-(2-azidoethoxy)methyl-4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine 
• 88150-46-3 2-(2-azidoethoxy)methyl-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine 
• 72509-76-3 ethyl methyl 1,4-dihydro-2,6-dimethyl-4(2,3-dichlorophenyl)-3,5-pyridinedicarboxylate 
• 1376615-40-5 (Z)-methyl 3-(2,3-dichlorophenyl)-2-(2-methyl-1,3-dioxolan-2-yl)acrylate 
• 1376615-47-2 (E)-ethyl 4-(2,3-dichlorophenyl)-5-((hydroxyimino)methyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate 
• 1376615-46-1 (E)-ethyl 5-((allyloxyimino)methyl)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate 
• 1376615-45-0 (1E,2E)-2-(2,3-dichlorobenzylidene)-3-oxobutanal O-allyl oxime 
• 1376615-44-9 (1E,2E)-3-(2,3-dichlorophenyl)-2-(2-methyl-1,3-dioxolan-2-yl)acrylaldehyde O-allyl oxime 
• 1376615-43-8 (1E,2E)-3-(2,3-dichlorophenyl)-2-(2-methyl-1,3-dioxolan-2-yl)acrylaldehyde oxime 
• 1376615-42-7 (E)-3-(2,3-dichlorophenyl)-2-(2-methyl-1,3-dioxolan-2-yl)acrylaldehyde 
• 1376615-41-6 (E)-3-(2,3-dichlorophenyl)-2-(2-methyl-1,3-dioxolan-2-yl)prop-2-en-1-ol 
• 113607-39-9 1,4-Dihydro-2,6-dimethyl-3-methoxycarbonyl-4-(2,3-dichlorophenyl)-5-(2-phthalimidoethoxy)carbonylpyridine 
• 111199-76-9 2-(cyanoimino)-6-(2,3-dichlorophenyl)-3,6-dihydro-4-methyl-5-pyrimidinecarboxylic acid, methyl ester 
• 176089-73-9 Methyl 5-cyano-4-(2,3-dichlorophenyl)-2-methyl-6-N-methylamino-1,4-dihydropyridine-3-carboxylate 

Relevant articles and documents

DRUG DERIVATIVES

The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.

DRUG DERIVATIVES

The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.

USE OF 1,2-BRIDGED 1,4-DIHYDROPYRIDINES AS MEDICAMENTS

The present invention relates to the new use of 1,2-bridged 1, 4-dihydropyridines which are known in some cases, of the general formula (I) STR1 in which R 1 to R 4 and a have the meaning indicated in the description, processes for their preparation and t